BURLINGAME, Calif.--(BUSINESS WIRE)--Inflammatix, a pioneering molecular diagnostics company, announced today the appointment of experienced medical device executive Amy Boyle as Chief Operating Officer, effective April 5, 2021. Ms. Boyle brings 30 years of broad commercial medical device experience to the company, with expertise in strategy, market development, sales and marketing, commercial operations, and manufacturing.
Most recently, Ms. Boyle served as Vice President, Strategy, Planning and Marketing for the Health Solutions division of Flex, helping to transform the company from a traditional electronics manufacturing service provider to a health solutions provider, which resulted in record bookings. Prior to that, she was Vice President, Marketing for the Urology division of Coloplast, where she led global expansion and growth of the surgical urology business and launched the endourology portfolio in the U.S. Previously, she served as Executive Vice President of Marketing for IMRIS, where she substantially grew system installations for the company’s image-guided therapies, repositioned the product value proposition, and drove product, regulatory and clinical strategies. Earlier, she spent five years at St. Jude Medical, first as Vice President, Marketing, International, responsible for cardiovascular businesses, and then as Vice President, Corporate Brand and Marketing, where she consistently exceeded revenue objectives for new product launches and launched a new corporate brand. Ms. Boyle also spent 17 years with Medtronic in a variety of sales roles in Canada and the U.S., including Regional Vice President of Sales for the Cardiac Rhythm Management business.
“We’re thrilled to welcome Amy to the executive team. She brings a deep understanding of the challenges and opportunities inherent in commercializing novel medical devices, and a track record of getting the best out of a company and its people,” said Inflammatix CEO Tim Sweeney, MD, PhD. “With our impending commercial launch, Amy’s insights and leadership will be instrumental in setting up Inflammatix for continued success now and into the future.”
“This is an important stage of Inflammatix’s growth as the company advances its first product – the InSep acute infection and sepsis test – towards commercialization and continues development of its deep pipeline. I am excited to join Tim and our talented team as we unleash the power of immune-response testing to create a new class of breakthrough diagnostics,” said Boyle.
“The addition of Amy to the executive team will also permit Inflammatix Co-Founder and Chief Business Officer Jonathan Romanowsky to grow the company’s business development and reimbursement efforts. Inflammatix looks forward to successfully commercializing a broad product pipeline and achieving our revenue targets,” said Sweeney.
About Inflammatix
Inflammatix is a molecular diagnostics company that is reimagining diagnostics by reading the patient’s immune system to deliver rapid results that improve patient care and reduce major public health burdens. The company’s initial focus is on acute infections and sepsis, where its tests combine proprietary biomarkers and advanced machine learning to help physicians quickly get the right treatments to the right patients. Each test will be developed to run on the company’s sample-to-answer isothermal instrument platform, Myrna, in under 30 minutes, enabling the power of precision medicine at the point of care. The Burlingame, Calif.-based company is funded by Khosla Ventures, Northpond Ventures, D1 Capital Partners, Think.Health Ventures, the Stanford StartX Fund, and OSF Ventures.
